Verona Pharma Surges to 397th in Market Rankings with $25.7 Million Turnover

On June 11, 2025, Verona Pharma (VRNA) saw a significant increase in trading volume, with a turnover of $25.7 million, marking a 197.42% rise from the previous day. This surge placed Verona Pharma at the 397th position in the day's stock market rankings. The stock price of Verona Pharma rose by 3.77%, marking its third consecutive day of gains, with a total increase of 6.77% over the past three days.

Cantor Fitzgerald has maintained its stock rating for Verona Pharma, reflecting a positive outlook on the company's performance. The firm has also raised its price target for Verona Pharma from $90.00 to $100.00, indicating confidence in the company's future prospects. Additionally, Roth Capital has set a price target of $83.00 for Verona Pharma, further supporting the bullish sentiment surrounding the stock.

Analysts have offered predictions for Verona Pharma's financial performance in the fiscal year 2026. Cantor Fitzgerald analyst O. Brayer anticipates that the company will achieve earnings per share of $12.56 for the year, highlighting the company's potential for growth and profitability. This optimistic forecast aligns with the firm's "Overweight" rating for Verona Pharma, suggesting that the stock is expected to outperform the broader market.